Skip to content

B Group, Inc.

Follow

13F filer, CIK 2043476, DALLAS, TX

B Group, Inc. reported $162,133,739 across 19 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 80.24% of the portfolio.

Accepted , ingested 13F-HR 0001420506-26-002733

Period
2026-09-30
Reported value
$162M
Holdings
19
Top 10 weight
80.24%
New
1
Sold out
1

Part of the filer group B Group, Inc.

  • B Group Capital LLC
  • Branden B. Muhl
How groups are built

Stakes and trades reported after 2026-09-30

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • RTSN RETENSION PHARMACEUTICALS IN: 13G 833,333 shares, 10% of the class, 13G filed 2026-10-16, 0001213900-26-110378Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
DRUGadded+27,500$1.37M
GPCRadded+40,000$1.25M
NRXPadded+185,433$541K
QTTBnew+65,000$538K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
IOVAreduced-1,075,000-$15.9M
ORKAreduced-20,000-$1.67M
SYREreduced-7,500-$668K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001420506-26-002733, largest first. % of portfolio is the value over $162,133,739, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
ADMAADMA BIOLOGICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,287,542 shares; 2025Q1: 2,317,542 shares; 2025Q2: 2,317,542 shares; 2025Q3: 2,412,542 shares; 2025Q4: 2,457,542 shares; 2026Q1: 3,207,542 shares; 2026Q2: 3,262,542 shares; 2026Q3: 3,262,542 shares 3,262,542$32.7M20.18%0Timeline
FTHFAETH THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 610,169 shares; 2026Q3: 610,169 shares 610,169$18.1M11.19%0Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 4,500,000 shares; 2026Q1: 11,414,285 shares; 2026Q2: 11,414,285 shares; 2026Q3: 11,414,285 shares 11,414,285$15.4M9.5%0Timeline
NRXPNRX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,000,000 shares; 2026Q2: 4,091,767 shares; 2026Q3: 4,277,200 shares 4,277,200$12.5M7.7%+185,433Timeline
ZLABZAI LAB LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 400,000 shares; 2025Q1: 400,000 shares; 2025Q2: 400,000 shares; 2025Q3: 400,000 shares; 2025Q4: 400,000 shares; 2026Q1: 450,646 shares; 2026Q2: 450,646 shares; 2026Q3: 450,646 shares 450,646$11.9M7.32%0Timeline
PRAXPRAXIS PRECISION MEDICINES IQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 19,000 shares; 2025Q2: 35,000 shares; 2025Q3: 31,500 shares; 2025Q4: 33,237 shares; 2026Q1: 33,237 shares; 2026Q2: 33,237 shares; 2026Q3: 33,237 shares 33,237$9.68M5.97%0Timeline
SGHTSIGHT SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 629,370 shares; 2025Q1: 833,600 shares; 2025Q2: 930,000 shares; 2025Q3: 930,000 shares; 2025Q4: 920,000 shares; 2026Q1: 970,000 shares; 2026Q2: 970,000 shares; 2026Q3: 970,000 shares 970,000$9.08M5.6%0Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 965,556 shares; 2025Q1: 1,255,556 shares; 2025Q2: 1,800,556 shares; 2025Q3: 1,800,556 shares; 2025Q4: 1,800,556 shares; 2026Q1: 1,800,556 shares; 2026Q2: 1,800,556 shares; 2026Q3: 1,800,556 shares 1,800,556$8.77M5.41%0Timeline
IOVAIOVANCE BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 992,000 shares; 2025Q1: 1,500,000 shares; 2025Q2: 1,500,000 shares; 2025Q3: 1,500,000 shares; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares; 2026Q2: 1,500,000 shares; 2026Q3: 425,000 shares 425,000$6.3M3.88%-1,075,000Timeline
GPCRSTRUCTURE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 90,000 shares; 2026Q1: 127,500 shares; 2026Q2: 140,000 shares; 2026Q3: 180,000 shares 180,000$5.63M3.47%+40,000Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 50,000 shares; 2025Q1: 70,000 shares; 2025Q2: 80,000 shares; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 100,000 shares; 2026Q2: 70,000 shares; 2026Q3: 62,500 shares 62,500$5.56M3.43%-7,500Timeline
CLLSCELLECTIS S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 3,081,501 shares; 2025Q1: 3,256,501 shares; 2025Q2: 3,256,501 shares; 2025Q3: 3,281,501 shares; 2025Q4: 3,281,501 shares; 2026Q1: 3,281,501 shares; 2026Q2: 3,281,501 shares; 2026Q3: 3,281,501 shares 3,281,501$4.96M3.06%0Timeline
AURAAURA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 472,576 shares; 2025Q1: 472,576 shares; 2025Q2: 572,576 shares; 2025Q3: 572,576 shares; 2025Q4: 572,576 shares; 2026Q1: 597,576 shares; 2026Q2: 764,243 shares; 2026Q3: 764,243 shares 764,243$4.8M2.96%0Timeline
DRUGBRIGHT MINDS BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 67,500 shares; 2026Q2: 67,500 shares; 2026Q3: 95,000 shares 95,000$4.73M2.92%+27,500Timeline
ORKAORUKA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 20,000 shares; 2025Q1: 58,215 shares; 2025Q2: 75,000 shares; 2025Q3: 75,000 shares; 2025Q4: 75,000 shares; 2026Q1: 75,000 shares; 2026Q2: 75,000 shares; 2026Q3: 55,000 shares 55,000$4.58M2.83%-20,000Timeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 50,651 shares; 2025Q1: 200,000 shares; 2025Q2: 189,350 shares; 2025Q3: 175,706 shares; 2025Q4: 175,706 shares; 2026Q1: 175,706 shares; 2026Q2: 175,706 shares; 2026Q3: 175,706 shares 175,706$4.13M2.55%0Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 7,596 shares; 2025Q1: 47,500 shares; 2025Q2: 110,000 shares; 2025Q3: 135,000 shares; 2025Q4: 135,000 shares; 2026Q1: 135,000 shares; 2026Q2: 135,000 shares; 2026Q3: 135,000 shares 135,000$2.03M1.25%0Timeline
FHTXFOGHORN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 102,000 shares; 2026Q2: 200,000 shares; 2026Q3: 200,000 shares 200,000$714K0.44%0Timeline
QTTBQ32 BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 65,000 shares 65,000$538K0.33%newTimeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
INVESCO QQQ TRINVESCO QQQ TR50,000$36.8Mput

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001420506-26-002733 base2026-11-16